20B Stock Chart & Stats
€0.31
>-€0.01(-0.64%)
At close: 4:00 PM EDT
€0.31
>-€0.01(-0.64%)
Day’s Range― - ―
52-Week Range€0.15 - €0.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€36.85M
Enterprise Value€48.82
Total Cash (Recent Filing)€1.01M
Total Debt (Recent Filing)€724.86K
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding106,483,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)180.94
Price to Sales (P/S)1001.91
P/FCF Ratio-54.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairReturning to positive equity in 2026 and limited absolute debt suggests solvency has materially improved versus prior negative-equity years. This durable repair reduces immediate insolvency risk, modestly extends runway and improves ability to negotiate financing or partnerships over the next several months.
Market & Product FocusA focused franchise in liquid-biopsy cancer diagnostics targets a structural, growing market for non-invasive cancer detection and monitoring. Proprietary tests and analytical methods can create enduring IP and recurring testing opportunities, supporting revenue potential and strategic partnerships over time.
Transparent Cash DynamicsClose alignment of net income and free cash flow indicates limited non-cash accounting noise, making cash-burn forecasting more reliable. That transparency helps management and investors plan financing needs and operational adjustments with greater confidence over a 2–6 month horizon.
Bears Say
Sustained Cash BurnPersistent operating and free-cash-flow deficits, and a ~47% deterioration in FCF in 2026, create a durable need for external capital. This ongoing burn constrains strategic flexibility, increases refinancing and dilution risk, and is the primary near-term threat to continuity absent new funding.
Declining Revenue & MarginsA shrinking top line and a negative gross profit signal product-market or cost-structure challenges. These fundamentals lengthen the runway to break-even, require sustained investment to rebuild demand or margin, and increase the capital needed to reach a stable, profitable scale.
Thin Capital BaseA history of negative equity and current thin equity relative to losses leaves limited buffer against shocks. That structural weakness elevates refinancing risk, limits ability to absorb further losses, and increases the likelihood of dilutive financing if growth or cash generation does not improve.
BioMark Diagnostics News
20B FAQ
What was BioMark Diagnostics’s price range in the past 12 months?
BioMark Diagnostics lowest stock price was €0.15 and its highest was €0.42 in the past 12 months.
What is BioMark Diagnostics’s market cap?
BioMark Diagnostics’s market cap is €36.85M.
When is BioMark Diagnostics’s upcoming earnings report date?
BioMark Diagnostics’s upcoming earnings report date is Aug 31, 2026 which is in 28 days.
How were BioMark Diagnostics’s earnings last quarter?
Currently, no data Available
Is BioMark Diagnostics overvalued?
According to Wall Street analysts BioMark Diagnostics’s price is currently Overvalued.
Does BioMark Diagnostics pay dividends?
BioMark Diagnostics does not currently pay dividends.
What is BioMark Diagnostics’s EPS estimate?
BioMark Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioMark Diagnostics have?
BioMark Diagnostics has 106,483,440 shares outstanding.
What happened to BioMark Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioMark Diagnostics?
Currently, no hedge funds are holding shares in DE:20B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioMark Diagnostics
BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Technical Analysis
Spectral Medical
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
ZYUS Life Sciences
―
Sona Nanotech Inc
―